RxDoctor Payments Data

Rebecca Doss, OD

Optometrist · Birmingham, ALNPI 1750601316

Payments from drug & device makers

$2,398in general payments, 2019–2025

Across 110 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$600
  • Alcon$380
  • Oyster Point Pharma, Inc.$347
  • AbbVie$311
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$171
  • Biotissue Holdings Inc.$109
  • plus $481 from 11 others

What the payments were for

  • Food & beverage$2,398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,398 in reported general payments places this provider in the 75th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$23,851
Medicare patients
122
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner11$20,039
XiidraLifitegrast29$19,446
RestasisCyclosporine22$14,319
Cyclosporine30$12,893
LumiganBimatoprost24$9,572
VyzultaLatanoprostene Bunod14$7,420
ZioptanTafluprost/Pf12$2,972
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$2,271
Fluorometholone23$1,791
Latanoprost111$1,045
Prednisolone Acetate21$989
ValacyclovirValacyclovir Hcl22$738
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat25$501
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha39$470
Timolol Maleate30$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$600$26,86643 claims
AbbVieRestasis, Lumigan$311$23,89246 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$18$20,03911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 749 optometrist providers in Alabama.

Other optometrist in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →